Innervation of human omental arteries and veins and vasomotor response to noradrenaline, neuropeptide Y, substance P and vasoactive intestinal peptide.
Human omental arteries and veins are supplied with nerve fibers containing noradrenaline (NA) and neuropeptide Y (NPY); these two agents probably co-exist in perivascular sympathetic nerve fibers. Substance P (SP)- or vasoactive intestinal peptide (VIP)-containing fibers could not be detected. In studies on isolated omental vessels NA produced constriction. The results of blockade experiments suggest that human omental arteries are equipped predominantly with alpha 1-adrenoceptors and omental veins with a mixture of alpha 1- and alpha 2-adrenoceptors. NPY at a concentration of 10(-7) M or higher had a weak contractile effect on veins and virtually no effect on arteries. NPY at a concentration of 3 X 10(-8) M shifted the NA concentration response curve to the left in arteries (pD2 = 5.8 for NA versus 6.6. for NA in the presence of NPY; P less than 0.001) but not in veins. Both SP and VIP relaxed arteries precontracted with NA or prostaglandin F2 alpha (PGF2 alpha). The potency of SP as a relaxant agent was similar in arteries and veins; the effect of VIP was elicited at lower concentrations in veins than in arteries.
Edvinsson
L
L
Håkanson
R
R
Steen
S
S
Sundler
F
F
Uddman
R
R
Wahlestedt
C
C
D000368:Aged; D001158:Arteries / Q000187:drug effects / Q000294:innervation; D015237:Dinoprost; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009419:Nerve Tissue Proteins / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects; D009478:Neuropeptide Y; D009638:Norepinephrine / Q000494:pharmacology*; D009852:Omentum / Q000098:blood supply*; D011224:Prazosin / Q000494:pharmacology; D011460:Prostaglandins F / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D012039:Regional Blood Flow / Q000187:drug effects; D013373:Substance P / Q000494:pharmacology*; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*; D014666:Vasomotor System / Q000187:drug effects*; D014680:Veins / Q000187:drug effects / Q000294:innervation; D015016:Yohimbine / Q000494:pharmacology
D009419:Nerve Tissue Proteins; D009478:Neuropeptide Y; D011460:Prostaglandins F; D011942:Receptors, Adrenergic, alpha; D015016:Yohimbine; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D015237:Dinoprost; D009638:Norepinephrine; D011224:Prazosin